Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

CAMP4 Therapeutics Corporation - Common Stock (NQ:CAMP)

6.190 -0.190 (-2.98%)
Streaming Delayed Price Updated: 1:55 PM EST, Dec 22, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about CAMP4 Therapeutics Corporation - Common Stock

News headline image
CAMP4 Announces Pricing of $30.0 Million Underwritten Offering of Common Stock
From CAMP4 Therapeutics
Via GlobeNewswire
News headline image
CAMP4 and GSK Enter Strategic Collaboration to Advance RNA-Based Therapeutic Discoveries
From CAMP4 Therapeutics
Via GlobeNewswire
News headline image
CAMP4 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From CAMP4 Therapeutics
Via GlobeNewswire
News headline image
CAMP4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From CAMP4 Therapeutics
Via GlobeNewswire
News headline image
CAMP4 Reports Third Quarter 2025 Financial Results and Corporate Highlights
From CAMP4 Therapeutics
Via GlobeNewswire
News headline image
CAMP4 Therapeutics Initiates GLP Toxicology Studies for CMP-SYNGAP-01
From CAMP4 Therapeutics
Via GlobeNewswire
News headline image
CAMP4 Announces an Oversubscribed Private Placement of up to $100 Million to Advance First-in-Class Treatment for SYNGAP1-Related Disorders
From CAMP4 Therapeutics
Via GlobeNewswire
News headline image
CAMP4 Reports Second Quarter 2025 Financial Results and Corporate Highlights
From CAMP4 Therapeutics
Via GlobeNewswire
News headline image
Sequans Appoints Jason W. Cohenour to Board of Directors
Paris, France--(Newsfile Corp. - June 30, 2025) - Sequans Communications S.A. (NYSE: SQNS), a leading innovator in cellular IoT semiconductor... 
Via Newsfile
News headline image
CAMP4 Presents Translational Data from SYNGAP1-Related Disorders Program Showcasing Increased Protein in Non-Human Primates and Reviews Preclinical and Detailed Single Ascending Dose Safety Data from Urea Cycle Disorders Program at the 28th American
From CAMP4 Therapeutics
Via GlobeNewswire
News headline image
CAMP4 Reports First Quarter 2025 Financial Results and Corporate Highlights
From CAMP4 Therapeutics
Via GlobeNewswire
News headline image
CAMP4 to Present New Preclinical Data from its Urea Cycle Disorders and SYNGAP1-Related Disorders Programs at the 28th American Society of Gene and Cell Therapy Annual Meeting
From CAMP4 Therapeutics
Via GlobeNewswire
News headline image
CAMP4 Reports Full Year 2024 Financial Results and Provides Corporate Update
From CAMP4 Therapeutics
Via GlobeNewswire
News headline image
CAMP4 Appoints Multiple Industry Veterans to its Board of Directors
From CAMP4 Therapeutics
Via GlobeNewswire
News headline image
CAMP4 to Participate in Upcoming Investor Conferences
From CAMP4 Therapeutics
Via GlobeNewswire
News headline image
CAMP4 to Present at the 43rd Annual J.P. Morgan Healthcare Conference
From CAMP4 Therapeutics
Via GlobeNewswire
News headline image
CAMP4 Provides Corporate Updates and Highlights Key Upcoming Milestones
From CAMP4 Therapeutics
Via GlobeNewswire
News headline image
CAMP4 Appoints John Maraganore and Rachel Meyers as Strategic Advisors
Industry veterans John Maraganore, Ph.D., and Rachel Meyers, Ph.D., to provide strategic guidance on the company’s RNA Actuating platform to develop a new class of RNA medicines that upregulate protein... 
From CAMP4 Therapeutics
Via GlobeNewswire
News headline image
CAMP4 to Participate in the Piper Sandler 36th Annual Healthcare Conference
From CAMP4 Therapeutics
Via GlobeNewswire
News headline image
CAMP4 Reports Third Quarter 2024 Financial Results
From CAMP4 Therapeutics
Via GlobeNewswire
News headline image
CAMP4 Announces Pricing of Initial Public Offering
From CAMP4 Therapeutics
Via GlobeNewswire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.